22 related articles for article (PubMed ID: 3007605)
1. Preclinical studies on angiotensin converting enzyme inhibitors.
Natoff IL
Cardiovasc Drugs Ther; 1987; 1(1):15-27. PubMed ID: 3154307
[TBL] [Abstract][Full Text] [Related]
2. Safety and tolerance of single oral doses of trandolapril (RU 44.570), a new angiotensin converting enzyme inhibitor.
Patat A; Surjus A; Le Go A; Granier J
Eur J Clin Pharmacol; 1989; 36(1):17-23. PubMed ID: 2537217
[TBL] [Abstract][Full Text] [Related]
3. Baroreflex setting and sensitivity in normal subjects: effects of pharmacologic inhibition of the angiotensin I converting enzyme.
Düsing R; Kayser G; Wagner S; Scherf H; Glänzer K; Predel HG; Kramer HJ
Am J Cardiol; 1987 Apr; 59(10):50D-54D. PubMed ID: 3034033
[TBL] [Abstract][Full Text] [Related]
4. The effect of the converting enzyme inhibitor HOE 498 on the renin angiotensin system of normal volunteers.
Bussien JP; Nussberger J; Porchet M; Waeber B; Brunner HR; Perisic M; Tansey MJ; Bomm M; Hajdu P
Naunyn Schmiedebergs Arch Pharmacol; 1985 Mar; 329(1):63-9. PubMed ID: 2987705
[TBL] [Abstract][Full Text] [Related]
5. Influence of the converting enzyme inhibitors Hoe 498, enalapril and captopril on vascular reactivity of isolated arterial preparations.
Schölkens BA; Xiang JZ; Tilly H
Clin Exp Hypertens A; 1984; 6(10-11):1807-13. PubMed ID: 6099766
[No Abstract] [Full Text] [Related]
6. Pharmacological properties of the new orally active angiotensin converting enzyme inhibitor 2-[N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-L-alanyl] -(1S,3S,5S)-2-azabicyclo[3.3.0]octane-3-carboxylic acid (Hoe 498).
Becker RH; Schölkens BA; Metzger M; Schulze KJ
Arzneimittelforschung; 1984; 34(10B):1411-6. PubMed ID: 6097267
[TBL] [Abstract][Full Text] [Related]
7. Pharmacodynamic effects of a single 10-mg dose of the angiotensin converting enzyme inhibitor ramipril in patients with impaired renal function.
Ocón-Pujadas J; Debusmann ER; Jane F; Lahn W; Irmisch R; Mora J; Grötsch H
J Cardiovasc Pharmacol; 1989; 13 Suppl 3():S45-8. PubMed ID: 2474101
[TBL] [Abstract][Full Text] [Related]
8. The present molecules of converting enzyme inhibitors.
Brunner HR; Nussberger J; Waeber B
J Cardiovasc Pharmacol; 1985; 7 Suppl 1():S2-11. PubMed ID: 2580170
[TBL] [Abstract][Full Text] [Related]
9. Physicochemical and enzyme binding kinetic properties of a new angiotensin-converting enzyme inhibitor ramipril and their clinical implications.
Bender N; Rangoonwala B; Rosenthal J; Vasmant D
Clin Physiol Biochem; 1990; 8 Suppl 1():44-52. PubMed ID: 2147879
[TBL] [Abstract][Full Text] [Related]
10. Ramipril. A review of its pharmacological properties and therapeutic efficacy in cardiovascular disorders.
Todd PA; Benfield P
Drugs; 1990 Jan; 39(1):110-35. PubMed ID: 2138076
[TBL] [Abstract][Full Text] [Related]
11. Unchanged pressor effect of norepinephrine in normal man following the oral administration of two angiotensin converting enzyme inhibitors, captopril and HOE 498.
Vierhapper H; Witte PU; Waldhäusl W
J Hypertens; 1986 Feb; 4(1):9-11. PubMed ID: 3007605
[TBL] [Abstract][Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
